Waldencast PLC

Waldencast PLC(WALD)股票分析

$0.879

-0.041 (-4.69%)收盘时

Loading chart…
最高
0.990
开盘
0.930
成交量加权均价
0.91
成交量
277.02K
市值
478.98M
最低
0.861
成交额
252.12K
企业价值/息税折旧摊销前利润(TTM)
-0.59

Waldencast plc is a global multi-brand beauty and wellness platform. It is focused on developing, acquiring, accelerating, and scaling conscious and purpose-driven brands. Its segments include Obagi Medical and Milk Makeup. The Obagi Medical segment sells advanced skincare products backed by science and formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines and wrinkles, and to protect and enhance skin tone and texture. Its portfolio of medical-grade skincare with consumer-centric, in-office injectable procedures includes Saypha ChIQ, and MagIQ lines of injectable hyaluronic acid gels. The Milk Makeup segment consists of the business of Milk. Its Milk’s business activities include developing, marketing, and selling cosmetics, skincare, and other beauty products. Its Milk Makeup segment offers over 250 products through its United States Website www.MilkMakeup.com and retail partners include Sephora globally and Ulta Beauty in the United States.

AI 分析 of Waldencast PLC (WALD)

卖出

Waldencast PLC is not a good buy right now due to significant financial losses and declining stock performance. The current price is $0.88, which is down 48.57% year-to-date. The RSI is at 26.413, indicating that the stock is oversold, but the forward P/E ratio is extremely high at 45.045, suggesting that the stock may be overvalued relative to its earnings potential. The main risk is the net margin, which was -140.03% in Q2 2025, indicating severe profitability issues.

估值指标

Waldencast PLC(WALD)当前预期市盈率为 45.05,5 年平均预期市盈率为 20.89。

预期市盈率

合理
5 年均值 P/E
20.89
当前P/E
45.05
高估
140.86
低估
-99.09

预期 EV/EBITDA

严重低估
5 年均值 EV/EBITDA
13.82
当前EV/EBITDA
-0.59
高估
20.28
低估
7.36

预期市销率

低估
5 年均值 P/S
1.79
当前P/S
0.35
高估
2.88
低估
0.69

Alphio AI 对 WALD 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%WALD

$3.01

情景价格

基

基准

基准 · 50%WALD

$2.59

情景价格

悲

悲观

悲观 · 25%WALD

$2.24

情景价格

事件时间线

2026-10-15 (ET)

17:00:00

Waldencast Files Form 15 to Terminate Registration

2026-09-24 (ET)

17:00:00

Waldencast Files Form 25 with SEC to Deregister Shares

2026-09-14 (ET)

07:00:00

Waldencast Announces Voluntary Delisting from Nasdaq

2026-09-01 (ET)

19:00:00

Middle East Violence Escalation Weighs on Markets, Tech Stocks Under Pressure

2026-06-15 (ET)

09:30:00

Waldencast Receives FDA Approval for Obagi saypha ChIQ Injectable Hyaluronic Acid Gel

资讯

WALD 常见问题 —— 由 Alphio AI 解答

Waldencast plc is a global multi-brand beauty and wellness platform. It is focused on developing, acquiring, accelerating, and scaling conscious and purpose-driven brands. Its segments include Obagi Medical and Milk Makeup. The Obagi Medical segment sells advanced skincare products backed by science and formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines and wrinkles, and to protect and enhance skin tone and texture. Its portfolio of medical-grade skincare with consumer-centric, in-office injectable procedures includes Saypha ChIQ, and MagIQ lines of injectable hyaluronic acid gels. The Milk Makeup segment consists of the business of Milk. Its Milk’s business activities include developing, marketing, and selling cosmetics, skincare, and other beauty products. Its Milk Makeup segment offers over 250 products through its United States Website www.MilkMakeup.com and retail partners include Sephora globally and Ulta Beauty in the United States. It operates in the Consumer Cyclicals sector (PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS industry).

Waldencast PLC is not a good buy right now due to significant financial losses and declining stock performance. The current price is $0.88, which is down 48.57% year-to-date. The RSI is at 26.413, indicating that the stock is oversold, but the forward P/E ratio is extremely high at 45.045, suggesting that the stock may be overvalued relative to its earnings potential. The main risk is the net margin, which was -140.03% in Q2 2025, indicating severe profitability issues.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易